Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study

被引:1
|
作者
Naranjo, Antonio [1 ,2 ]
Caceres, Laura [1 ,2 ]
Hernandez-Beriain, Jose Angel [3 ,5 ]
Francisco, Felix [1 ,2 ]
Ojeda, Soledad [1 ,2 ]
Talaverano, Sigrid
Novoa-Medina, Javier [5 ]
Adan Martin, Jose [4 ]
Delgado, Esmeralda
Trujillo, Elisa
Alvarez, Ftima
Magdalena, Laura
Rodriguez-Lozano, Carlos [1 ,2 ,6 ]
机构
[1] Hosp Univ Gran Canaria Dr Negrin, Serv Reumatol, Gran Canaria, Spain
[2] Univ Las Palmas Gran Canaria, Gran Canaria, Spain
[3] Complejo Hosp Univ Materno Insular Gran Canaria, Serv Reumatol, Gran Canaria, Spain
[4] Hosp Dr Molina Orosa, Serv Reumatol, Molina Orosa, Lanzarote, Spain
[5] Hosp Univ Canarias, Serv Reumatol, Tenerife, Spain
[6] Hosp Univ Nuestra Senora Candelaria, Serv Reumatol, Tenerife, Spain
来源
REUMATOLOGIA CLINICA | 2016年 / 12卷 / 01期
关键词
Rheumatoid arthritis; Treat-to-target; Health care quality; Adherence; DAS28; quality indicators;
D O I
10.1016/j.reuma.2015.03.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective:To analyze compliance with t2t clinical practice guidelines. Methods:Cross-sectional observational study in consecutive patients with rheumatoid arthritis (RA) in 5 hospitals in the Canary Islands. Patients filled out activity scales, HAQ and answered the question of whether the doctor had explained the treatment target. The rheumatologist also collected: visits in the past year, use of activity indices and HAQ, DAS28 of current visit and date of the next visit. The percentage of compliance to indicators based on the t2t recommendations (R) 1, 3, 5-7 and 10 was analyzed. Results:A total of 343 patients were recruited, 77% female, mean age 57, RA duration of 10 years. Median visits in the last year were 3 and mean time between last and current visit was 5.6 months. A total of 93% of the patients were treated with DMARDs and 44% were in remission by DAS (R1). In the previous visit, documented joint count was present in 85%, a HAQ in 19%, patient VAS in 41%, and a DAS28 in 35% of the patients (R6). The next visit was scheduled at an average of 4.3 months (R5). In 64% of patients with DAS28> 3.2 a visit between one and 3 months was scheduled (R5). A total of 96% of patients said they had been informed of the treatment target (R10). Variability between centers existed but was moderate. The only factor determining the performance of a DAS28 in the last visit was the patient's center of origin. Conclusion:The Canary Island centers studied achieved high levels of remission and low activity in their patients. The performance of composite indices and follow-up frequency recommended by the t2t are met, although there is room for improvement. (C) 2014 Elsevier Espana, S.L.U.y Sociedad Espanola de Reumatologia y Colegio Mexicano de Reumatologia. All rights reserved.
引用
下载
收藏
页码:34 / 38
页数:5
相关论文
共 50 条
  • [1] Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis
    Batko, Bogdan
    Batko, Krzysztof
    Krzanowski, Marcin
    Zuber, Zbigniew
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (09)
  • [2] Treat-to-target in rheumatoid arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2020, 2 (04): : E208 - E208
  • [3] Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan
    Kaneko, Yuko
    Koike, Takao
    Oda, Hiromi
    Yamamoto, Kazuhiko
    Miyasaka, Nobuyuki
    Harigai, Masayoshi
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2015, 25 (01) : 43 - 49
  • [4] Treat-to-Target Strategies in Rheumatoid Arthritis
    van der Hem-van Mil, Annette H. M.
    Huizinga, Tom W. J.
    Bloem, Johan L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (01): : 83 - 83
  • [5] Treat-to-Target Approach in Daily Clinical Practice in Pakistani Patients with Early Rheumatoid Arthritis
    Farman, Sumaira
    Ahmad, Nighat Mir
    Saeed, Muhammad Ahmed
    Asad, Kanwal
    Shabbir, Ghulam
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2015, 25 (02): : 129 - 133
  • [6] Treat-to-target in rheumatoid arthritis — are we there yet?
    Ronald van Vollenhoven
    Nature Reviews Rheumatology, 2019, 15 : 180 - 186
  • [7] Treat-to-target in rheumatoid arthritis - are we there yet?
    van Vollenhoven, Ronald
    NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (03) : 180 - 186
  • [8] Treat-to-target in rheumatoid arthritis: clinical and pharmacoeconomic considerations. Introduction
    Turchetti, G.
    Smolen, J. S.
    Kavanaugh, A.
    Braun, J.
    Pincus, T.
    Bombardieri, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : S1 - S1
  • [9] Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice
    Gazitt, Tal
    Oren, Shirley
    Reitblat, Tatiana
    Lidar, Merav
    Gurman, Alexandra Balbir
    Rosner, Itzhak
    Halabe, Nimer
    Feld, Joy
    Kassem, Sameer
    Lavi, Idit
    Elkayam, Ori
    Zisman, Devy
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2019, 6 (03) : 136 - 141
  • [10] What is the optimal target for treat-to-target strategies in rheumatoid arthritis?
    Bergstra, Sytske Anne
    Allaart, Cornelia F.
    CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (03) : 282 - 287